ARS Pharmaceuticals, Inc.
SPRY
$5.23
-$0.16-2.97%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -2.84% | -46.69% | 19.21% | -13.97% | -32.24% |
| Total Depreciation and Amortization | 4.79% | -4.80% | 6.65% | 40.14% | -0.36% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 107.11% | 36.70% | 2.13% | -22.35% | 84.82% |
| Change in Net Operating Assets | -249.30% | 215.19% | -597.48% | 6.79% | 88.98% |
| Cash from Operations | -35.56% | -3.36% | 7.57% | -18.83% | 2.82% |
| Capital Expenditure | -- | -- | 100.00% | -286.27% | 43.96% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 49.59% | 15.25% | 153.85% | -192.11% | 66.77% |
| Cash from Investing | 49.59% | 15.25% | 153.61% | -192.61% | 67.12% |
| Total Debt Issued | -- | -- | -101.53% | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,167.74% | -96.52% | 271.61% | -82.24% | 272.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 2,385.57% | -88.51% | -53.52% | -- | -- |
| Cash from Financing | 1,910.69% | -85.94% | -98.87% | 3,609.49% | 272.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 4.93% | 6.82% | -327.52% | -31.34% | 206.60% |